Submitted:
12 August 2025
Posted:
13 August 2025
You are already at the latest version
Abstract
Background: Percutaneous needle fasciotomy has been practiced for many years as a therapeutic alternative to open fasciectomy in Dupuytren's disease. In addition to collagenase injection, it had established itself as a minimally invasive procedure in everyday clinical practice. This study analyzes the treatment results of 1146 patients. Methods: Patients at a center for needle fasciotomy were surveyed retrospectively by means of a questionnaire. In addition to previous illnesses and the localization and number of affected fingers, the frequency of recurrences, the need for renewed treatment and satisfaction with the surgical result were also surveyed. Results: Between 1994 and 2012, 1146 patients with 1803 finger rays were treated and their data analyzed on the basis of records. In addition, a questionnaire survey on patient satisfaction was conducted and 174 questionnaires were analyzed. 83% of the patients were male, 16% female. In 50% of cases the right side was treated, in 45% of cases the left side (5% unknown). 46% of the finger rays treated were on the little finger and ring finger. In all but one case, an improvement in the contracture was achieved. Complications included skin tears (264 cases), increased swelling (5 cases), hypesthesia (1 case), flexor tendon rupture (4 cases) and a mid-limb base fracture (1 case). The mean operation time was 26.9 minutes, the duration of pain was 2.7 days, and patient satisfaction on a scale of 1-10 was 7.2. 77% of patients stated that there had been a further deterioration or recurrence within one year of treatment, and 35% of these patients stated that further treatment was necessary. Conclusion: Needle fasciotomy is a safe and effective method with a low complication rate, but targeted and stringent follow-up treatment is necessary, as is information about possible recurrences or further deterioration of the result.
Keywords:
1. Introduction
2. Materials and Methods
3. Results
| Stage prä OP | n | Improvement stage |
| N | 66 | - 0,88 |
| 0 | 2 | 0,00 |
| 1 | 594 | -0,97 |
| 2 | 570 | -1,86 |
| 3 | 416 | -2,55 |
| 4 | 155 | -3,02 |
| Stage | Complications | Σ | |||||||||
| -1 | 0 | 1 | 3 | 4 | 5 | 6 | 8 | all | compl | ||
| -1 | 1,5% | 90,9% | 7,6% | 0,0% | 0,0% | 0,0% | 0,0% | 0,0% | 100% | 7,58% | |
| 0 | 0,0% | 100,0% | 0,0% | 0,0% | 0,0% | 0,0% | 0,0% | 0,0% | 100% | 0,00% | |
| 1 | 0,2% | 91,8% | 7,9% | 0,2% | 0,0% | 0,0% | 0,0% | 0,0% | 100% | 8,08% | |
| 2 | 0,0% | 87,5% | 11,9% | 0,4% | 0,0% | 0,0% | 0,2% | 0,0% | 100% | 12,46% | |
| 3 | 0,0% | 79,6% | 19,0% | 0,0% | 0,2% | 0,2% | 0,7% | 0,2% | 100% | 20,43% | |
| 4 | 0,0% | 56,8% | 41,9% | 1,3% | 0,0% | 0,0% | 0,0% | 0,0% | 100% | 43,23% | |




4. Discussion
5. Conclusions
6. Patents
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Badois FJ, Lermusiaux JL, Massé C, Kuntz D. Traitement non chirurgical de la maladie de Dupuytren par aponevrotomie a l’aiguille. Rev Rhum Ed Fr 1993, 60, 808–813. [Google Scholar]
- Bleton R, Marcireau D, Almot J-Y, Treatment of Dupuytren disease by percutaneous needle fasciotomy. In Saffer P, Amadio PC,Foucher G, eds. Current practice in hand surgery. London: Martin Dunitz, 1997:187–193.
- Lermusiaux JL, Debeyre N. Le traitement medical de la malidie de Dupuytren. Rhumatologique. Expans. Sci. 1979, 338–343. [Google Scholar]
- Jurisic D, Kovic I, Lulic I, Stanec Z, Kapovic M, Uravic M. Dupuytren disease characteristics in Primorsko-goranska County, Croatia. Coll Antropol 2008, 32, 1209–1213. [Google Scholar]
- Tonkin MA, Burke FD, Varian JP. Dupuytren contracture, a comparative study of fasciectomy and dermofasciectomy in one hundred patients. J Hand Surg 1984, 9B, 156–162. [Google Scholar]
- Ullah AS, Dias JJ, Bhowal B. Does a “firebreak” full-thickness Skin graft prevent recurrence after surgery for Dupuytren contracture? A prospective, randomised trial. J Bone Joint Surg 2009, 91B, 374–378. [Google Scholar]
- Gelberman RH, Amiel D, Rudolph RM, Vance RM. Dupuytren contracture. An electron microscopic, biochemical, and clinical correlative study. J Bone Joint Surg 1980, 62A, 425–432. [Google Scholar]
- Dias JJ, Braybrooke J. Dupuytren contracture, an audit of the outcomes of surgery. J Hand Surg 2006, 31B, 514–521. [Google Scholar]
- Citron ND, Nunez V. Recurrence after surgery for Dupuytren disease, a randomized trial of two skin incisions. J Hand Surg 2005, 30B, 563–566. [Google Scholar]
- Hueston, JT. Recurrent Dupuytren contracture. Plast Reconstr Surg 1963, 31, 66–69. [Google Scholar] [CrossRef] [PubMed]
- Cools H, Verstreken J. The open palm technique in the treatment of Dupuytren disease. Acta Orthop Belg 1994, 60, 413–420. [Google Scholar]
- Adam RF, Loynes RD. Prognosis in Dupuytren disease. J Hand Surg 1992, 17A, 312–317. [Google Scholar]
- Foucher G, Cornil C, Lenoble E. Open palm technique for Dupuytren disease. A five-Year Follow-up. Ann Chir Main Memb Super 1992, 11, 362–366. [Google Scholar]
- Nieminen S, Lehto M. Resection of the palmaris longus tendon in surgery for Dupuytren contracture. Ann Chir Gynaecol 1986, 75, 164–167. [Google Scholar]
- van Rijssen AL, Werker PN. Percutaneous needle fasciotomy in Dupuytren disease. J Hand Surg 2006, 31B, 498–501. [Google Scholar]
- Nydick JA, Olliff BW, Garcia MJ, Hess AV, Stone JDA comparison of percutaneous needle fasciotomy and collagenase injection for Dupuytren disease. J. Hand Surg. 2013, 38, 2377–2380. [CrossRef] [PubMed]
- Beaudreuil J, Lellouche H, Orcel P, Bardin T. Needle aponeurotomy in Dupuytren's disease. Jt. Bone Spine 2012, 79, 13–16. [Google Scholar] [CrossRef] [PubMed]
- Strömberg, J. , Sörensen, A. I., & Fridén, J. Percutaneous needle fasciotomy versus collagenase treatment for Dupuytren contracture, a randomized controlled trial with a two-year follow-up. JBJS 2018, 100, 1079–1086. [Google Scholar]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).